{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:12:45Z","timestamp":1792843965498,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11102-026-01661-1","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:54:44Z","timestamp":1774425284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study"],"prefix":"10.1007","volume":"29","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M. K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Strasburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen E.","family":"Georgescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bidlingmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionela","family":"Baciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe F.","family":"Casanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Gilis-Januszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Manners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Bar-Ilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria La","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie Turich","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.J.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"11","key":"1661_CR1","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4158\/GL-2019-0405","volume":"25","author":"KCJ Yuen","year":"2019","unstructured":"Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM et al (2019) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract 25(11):1191\u20131232. https:\/\/doi.org\/10.4158\/GL-2019-0405","journal-title":"Endocr Pract"},{"issue":"10444","key":"1661_CR2","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1016\/S0140-6736(24)00342-8","volume":"403","author":"M Fleseriu","year":"2024","unstructured":"Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S (2024) Hypopituitarism. Lancet 403(10444):2632\u20132648. https:\/\/doi.org\/10.1016\/S0140-6736(24)00342-8","journal-title":"Lancet"},{"issue":"12","key":"1661_CR3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1507\/endocrj.EJ15-0337","volume":"62","author":"L Giovannini","year":"2015","unstructured":"Giovannini L, Tirabassi G, Muscogiuri G, Di Somma C, Colao A, Balercia G (2015) Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]. Endocr J 62(12):1037\u20131048. https:\/\/doi.org\/10.1507\/endocrj.EJ15-0337","journal-title":"Endocr J"},{"issue":"5","key":"1661_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S2213-8587(15)00098-4","volume":"3","author":"D Mo","year":"2015","unstructured":"Mo D, Fleseriu M, Qi R, Jia N, Child CJ, Bouillon R et al (2015) Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3(5):331\u2013338. https:\/\/doi.org\/10.1016\/S2213-8587(15)00098-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1661_CR5","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1210\/jc.2011-0179","volume":"96","author":"ME Molitch","year":"2011","unstructured":"Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(6):1587\u20131609. https:\/\/doi.org\/10.1210\/jc.2011-0179","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1661_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4158\/EP.14.2.143","volume":"14","author":"RG Rosenfeld","year":"2008","unstructured":"Rosenfeld RG, Bakker B (2008) Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 14(2):143\u2013154. https:\/\/doi.org\/10.4158\/EP.14.2.143","journal-title":"Endocr Pract"},{"key":"1661_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2147\/PPA.S239196","volume":"14","author":"M McNamara","year":"2020","unstructured":"McNamara M, Turner-Bowker DM, Westhead H, Yaworsky A, Palladino A, Gross H et al (2020) Factors driving patient preferences for growth hormone deficiency (GHD) injection regimen and injection device features: a discrete choice experiment. Patient Pref Adher 14:781\u2013793. https:\/\/doi.org\/10.2147\/PPA.S239196","journal-title":"Patient Pref Adher"},{"key":"1661_CR8","doi-asserted-by":"publisher","unstructured":"Cohen-Sela E, Oren A, Perl L, Regev R, Becker AS, Eyal O et al (2025) Introduction of Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Insights from a National Survey of Pediatric Endocrinologists. https:\/\/doi.org\/10.1016\/j.eprac.2025.11.008. Endocr Pract","DOI":"10.1016\/j.eprac.2025.11.008"},{"issue":"6","key":"1661_CR9","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1210\/clinem\/dgz149","volume":"105","author":"BS Miller","year":"2020","unstructured":"Miller BS, Velazquez E, Yuen KCJ (2020) Long-acting growth hormone preparations - current status and future considerations. J Clin Endocrinol Metab 105(6):e2121-2133. https:\/\/doi.org\/10.1210\/clinem\/dgz149","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1661_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13023-025-03898-8","volume":"20","author":"J Woelfle","year":"2025","unstructured":"Woelfle J, Kreitschmann-Andermahr I, Strasburger CJ, Pittrow DB, Pausch C, Schnabel D (2025) First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry. Orphanet J Rare Dis 20(1):372. https:\/\/doi.org\/10.1186\/s13023-025-03898-8","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1661_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101840","volume":"37","author":"KCJ Yuen","year":"2023","unstructured":"Yuen KCJ (2023) Best practice and research clinical endocrinology and metabolism focusing on growth hormone deficiency in adults - new perspectives. Best Pract Res Clin Endocrinol Metab 37(6):101840. https:\/\/doi.org\/10.1016\/j.beem.2023.101840","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1661_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1254231","volume":"11","author":"MS Grillo","year":"2023","unstructured":"Grillo MS, Frank J, Saenger P (2023) Long acting growth hormone (LAGH), an update. Front Pediatr 11:1254231. https:\/\/doi.org\/10.3389\/fped.2023.1254231","journal-title":"Front Pediatr"},{"issue":"4","key":"1661_CR13","doi-asserted-by":"publisher","first-page":"e1358","DOI":"10.1210\/clinem\/dgaa049","volume":"105","author":"G Johannsson","year":"2020","unstructured":"Johannsson G, Gordon MB, Hojby Rasmussen M, Hakonsson IH, Karges W, Svaerke C et al (2020) Once-weekly somapacitan is effective and well tolerated in adults with gh deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab 105(4):e1358\u20131376. https:\/\/doi.org\/10.1210\/clinem\/dgaa049","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1661_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17446651.2023.2290495","volume":"19","author":"EP Velazquez","year":"2024","unstructured":"Velazquez EP, Miller BS, Yuen KCJ (2024) Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products. Expert Rev Endocrinol Metab 19(1):1\u201310. https:\/\/doi.org\/10.1080\/17446651.2023.2290495","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"4","key":"1661_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ecl.2025.06.005","volume":"54","author":"KCJ Yuen","year":"2025","unstructured":"Yuen KCJ, Boguszewski MCS (2025) Long-acting growth hormone preparations. Endocrinol Metab Clin North Am 54(4):665\u2013684. https:\/\/doi.org\/10.1016\/j.ecl.2025.06.005","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"1661_CR16","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1210\/jc.2016-3547","volume":"102","author":"N Zelinska","year":"2017","unstructured":"Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L et al (2017) Long-acting c-terminal peptide-modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab 102(5):1578\u20131587. https:\/\/doi.org\/10.1210\/jc.2016-3547","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1661_CR17","doi-asserted-by":"publisher","first-page":"e2717","DOI":"10.1210\/clinem\/dgac220","volume":"107","author":"CL Deal","year":"2022","unstructured":"Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M et al (2022) Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab 107(7):e2717\u2013e2728. https:\/\/doi.org\/10.1210\/clinem\/dgac220","journal-title":"J Clin Endocrinol Metab"},{"key":"1661_CR18","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ24-0625","author":"R Horikawa","year":"2025","unstructured":"Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG et al (2025) Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study. Endocr J. https:\/\/doi.org\/10.1507\/endocrj.EJ24-0625","journal-title":"Endocr J"},{"key":"1661_CR19","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.galenos.2025.2025-6-24","author":"MH Awad","year":"2025","unstructured":"Awad MH, Ghanim R, Eladl R, Mughal Z, Mustafa M (2025) Real-world efficacy of weekly somatrogon on growth and bone health in pediatric growth hormone deficiency: a 12-month retrospective cohort study. J Clin Res Pediatr Endocrinol. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2025.2025-6-24","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"4","key":"1661_CR20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82998","volume":"17","author":"S Katsoudas","year":"2025","unstructured":"Katsoudas S, Tsitsekli E, Pichlinski I, Techlemetzi N, Galanopoulou E, Polychroni I et al (2025) Comparative efficacy of once-weekly Somatrogon versus daily growth hormone therapy in children with idiopathic growth hormone deficiency: a real-world retrospective study from Greece. Cureus 17(4):e82998. https:\/\/doi.org\/10.7759\/cureus.82998","journal-title":"Cureus"},{"issue":"5","key":"1661_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/cpdd.414","volume":"7","author":"WG Kramer","year":"2018","unstructured":"Kramer WG, Jaron-Mendelson M, Koren R, Hershkovitz O, Hart G (2018) Pharmacokinetics, pharmacodynamics, and safety of a long-acting human growth hormone (MOD-4023) in healthy Japanese and Caucasian adults. Clin Pharmacol Drug Dev 7(5):554\u2013563. https:\/\/doi.org\/10.1002\/cpdd.414","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"1661_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1530\/EJE-16-0748","volume":"176","author":"CJ Strasburger","year":"2017","unstructured":"Strasburger CJ, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L et al (2017) MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults. Eur J Endocrinol 176(3):283\u2013294. https:\/\/doi.org\/10.1530\/EJE-16-0748","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1661_CR23","doi-asserted-by":"publisher","first-page":"6431","DOI":"10.1210\/jc.2005-0928","volume":"90","author":"AR Hoffman","year":"2005","unstructured":"Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L et al (2005) Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab 90(12):6431\u20136440. https:\/\/doi.org\/10.1210\/jc.2005-0928","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1661_CR24","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1210\/jc.2013-3059","volume":"99","author":"M Bidlingmaier","year":"2014","unstructured":"Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J et al (2014) Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 99(5):1712\u20131721. https:\/\/doi.org\/10.1210\/jc.2013-3059","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1661_CR25","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1210\/jcem.84.11.6113","volume":"84","author":"DM Cook","year":"1999","unstructured":"Cook DM, Ludlam WH, Cook MB (1999) Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab 84(11):3956\u20133960. https:\/\/doi.org\/10.1210\/jcem.84.11.6113","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1661_CR26","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R et al (2016) Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101(11):3888\u20133921. https:\/\/doi.org\/10.1210\/jc.2016-2118","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1661_CR27","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1210\/jcem.85.3.6463","volume":"85","author":"JP Span","year":"2000","unstructured":"Span JP, Pieters GF, Sweep CG, Hermus AR, Smals AG (2000) Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 85(3):1121\u20131125. https:\/\/doi.org\/10.1210\/jcem.85.3.6463","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1661_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ghir.2010.01.003","volume":"20","author":"K Chihara","year":"2010","unstructured":"Chihara K, Fujieda K, Shimatsu A, Miki T, Tachibana K (2010) Dose-dependent changes in body composition during growth hormone (GH) treatment in Japanese patients with adult GH deficiency: a randomized, placebo-controlled trial. Growth Horm IGF Res 20(3):205\u2013211. https:\/\/doi.org\/10.1016\/j.ghir.2010.01.003","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"1661_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11102-014-0571-z","volume":"18","author":"CB Newman","year":"2015","unstructured":"Newman CB, Carmichael JD, Kleinberg DL (2015) Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials. Pituitary 18(3):297\u2013305. https:\/\/doi.org\/10.1007\/s11102-014-0571-z","journal-title":"Pituitary"},{"issue":"26","key":"1661_CR30","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM198912283212605","volume":"321","author":"F Salomon","year":"1989","unstructured":"Salomon F, Cuneo RC, Hesp R, Sonksen PH (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321(26):1797\u20131803. https:\/\/doi.org\/10.1056\/NEJM198912283212605","journal-title":"N Engl J Med"},{"issue":"6","key":"1661_CR31","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/cen.15298","volume":"103","author":"SC Chen","year":"2025","unstructured":"Chen SC, Lucas-Herald AK, Tang R, Tseretopoulou X, Alimussina M, Andrews D et al (2025) Development of a minimum dataset for the global monitoring of the safety and efficacy of growth hormone replacement in adults with growth hormone deficiency (AGHD). Clin Endocrinol (Oxf) 103(6):841\u2013851. https:\/\/doi.org\/10.1111\/cen.15298","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1661_CR32","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.1321","author":"BM Biller","year":"2024","unstructured":"Biller BM, Gilis-Januszewska A, Doknic M, Pico AM, Fleseriu M, Raverot G et al (2024) 12542 results of the Foresight Trial support the efficacy and safety of once-weekly lonapegsomatropin in adults with growth hormone deficiency (GHD). J Endocr Soc. https:\/\/doi.org\/10.1210\/jendso\/bvae163.1321","journal-title":"J Endocr Soc"},{"issue":"5","key":"1661_CR33","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1210\/jc.2003-030840","volume":"89","author":"P Maison","year":"2004","unstructured":"Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 89(5):2192\u20132199. https:\/\/doi.org\/10.1210\/jc.2003-030840","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1661_CR34","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1038\/s41598-025-88167-1","volume":"15","author":"Y Shao","year":"2025","unstructured":"Shao Y, Wang N, Shao M, Liu B, Wang Y, Yang Y et al (2025) The lean body mass to visceral fat mass ratio is negatively associated with cardiometabolic disorders: a cross-sectional study. Sci Rep 15(1):3422. https:\/\/doi.org\/10.1038\/s41598-025-88167-1","journal-title":"Sci Rep"},{"issue":"11","key":"1661_CR35","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.numecd.2016.06.011","volume":"26","author":"A Spahillari","year":"2016","unstructured":"Spahillari A, Mukamal KJ, DeFilippi C, Kizer JR, Gottdiener JS, Djousse L et al (2016) The association of lean and fat mass with all-cause mortality in older adults: the Cardiovascular Health Study. Nutr Metab Cardiovasc Dis 26(11):1039\u20131047. https:\/\/doi.org\/10.1016\/j.numecd.2016.06.011","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"1661_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.035006","volume":"14","author":"KL Yan","year":"2025","unstructured":"Yan KL, Liang I, Ravellette K, Gornbein J, Srikanthan P, Horwich TB (2025) Body composition risk assessment of all-cause mortality in patients with coronary artery disease completing cardiac rehabilitation. J Am Heart Assoc 14(5):e035006. https:\/\/doi.org\/10.1161\/JAHA.124.035006","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"1661_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000524600","volume":"95","author":"R Horikawa","year":"2022","unstructured":"Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG et al (2022) Efficacy and safety of once-weekly somatrogon compared with once-daily somatropin (Genotropin(R)) in Japanese children with pediatric growth hormone deficiency: results from a randomized phase 3 study. Horm Res Paediatr 95(3):275\u2013285. https:\/\/doi.org\/10.1159\/000524600","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"1661_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1515\/jpem-2022-0359","volume":"36","author":"Z Zadik","year":"2023","unstructured":"Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievsky O, Mauras N et al (2023) An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment. J Pediatr Endocrinol Metab 36(3):261\u2013269. https:\/\/doi.org\/10.1515\/jpem-2022-0359","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01661-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01661-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01661-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:01:41Z","timestamp":1779278501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01661-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1661"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01661-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pfizer\u2019s generative artificial intelligence (AI)-assisted technology was used in the production of this manuscript. Specifically, the AI tool was used to help develop the first draft of the methods and results in the manuscript. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"NCT01909479.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Registration number"}},{"value":"MF: Research grant: Ascendis; Consulting fee: Novo Nordisk; Member of Pituitary editorial board. BMKB: Research grant: Ascendis; Consultant: Ascendis, Pfizer, Novo Nordisk; at the time of this study which closed over 6 years ago, BMKB served as the PI of a research grant to Massachusetts General Hospital from Prolor and as an occasional consultant to the company. SMW, CG, IB, FFC: No conflicts of interest. CJS: Research grant: OPKO Health, Inc.; Consultant\/speaker: Prolor\/OPKO Health Inc., Novo Nordisk, Sandoz Hexal, Pfizer, Ascendis, Crinetics. MB: Research grant: OPKO Health, Inc.; Speaker\/consultant: Novo Nordisk, Sandoz Hexal, Pfizer, Ascendis, IDS, Roche, Diasorin. CW: Research grant: Ascendis. AG-J: Speaker: Recordati, Novo Nordisk, Ipsen, Ascendis, Pfizer. GH, AB-I: Employee of OPKO Biologics. AM: Employee of OPKO Pharmaceuticals LLC. JC: Employee of OPKO Health Inc. MC: Employee of Pfizer. DLT, CTT: Employee of and owns stock in Pfizer. KCJY: Research grant: Ascendis, Novo Nordisk; Consultant: Novo Nordisk, Ascendis, Pfizer; Member of Pituitary editorial board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}